Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) have earned a consensus rating of “Moderate Buy” from the thirteen brokerages that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation and eight have issued a buy recommendation on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $78.80.

Several research firms recently weighed in on HALO. TD Cowen upped their price objective on shares of Halozyme Therapeutics from $79.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. HC Wainwright reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Thursday, January 29th. Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, February 3rd. Citigroup reaffirmed a “market outperform” rating on shares of Halozyme Therapeutics in a report on Tuesday, November 4th. Finally, JPMorgan Chase & Co. upped their target price on shares of Halozyme Therapeutics from $63.00 to $65.00 and gave the stock a “neutral” rating in a research report on Monday, October 27th.

Halozyme Therapeutics Price Performance

Halozyme Therapeutics stock opened at $79.44 on Tuesday. The stock has a market cap of $9.34 billion, a price-to-earnings ratio of 16.72, a PEG ratio of 0.33 and a beta of 0.97. The company has a quick ratio of 1.37, a current ratio of 1.59 and a debt-to-equity ratio of 1.59. The business has a 50-day simple moving average of $71.18 and a 200 day simple moving average of $70.10. Halozyme Therapeutics has a 52 week low of $47.50 and a 52 week high of $82.22.

Insider Transactions at Halozyme Therapeutics

In related news, Director Bernadette Connaughton sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $70.25, for a total value of $140,500.00. Following the completion of the sale, the director owned 40,123 shares in the company, valued at $2,818,640.75. The trade was a 4.75% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $76.12, for a total value of $1,522,400.00. Following the completion of the sale, the chief executive officer directly owned 708,719 shares of the company’s stock, valued at approximately $53,947,690.28. This represents a 2.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 49,398 shares of company stock valued at $3,650,592 over the last quarter. Company insiders own 2.90% of the company’s stock.

Institutional Investors Weigh In On Halozyme Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Root Financial Partners LLC bought a new position in shares of Halozyme Therapeutics during the 3rd quarter valued at $25,000. Larson Financial Group LLC boosted its position in Halozyme Therapeutics by 3,118.2% during the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 343 shares during the period. Measured Wealth Private Client Group LLC grew its stake in shares of Halozyme Therapeutics by 51.5% during the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 124 shares during the last quarter. Richardson Financial Services Inc. increased its holdings in shares of Halozyme Therapeutics by 87.6% in the third quarter. Richardson Financial Services Inc. now owns 424 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 198 shares during the period. Finally, Clearstead Advisors LLC increased its holdings in shares of Halozyme Therapeutics by 107.7% in the third quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 265 shares during the period. 97.79% of the stock is currently owned by institutional investors.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.